Loading clinical trials...
Loading clinical trials...
A Phase 1, Multi-center, Parallel, Open-label, Pharmacokinetic, Safety, and Tolerability Study of Venglustat Given as a Single Dose in Adult Participants With Mild, Moderate, and Severe Hepatic Impairment and in Matched Participants With Normal Hepatic Function
Conditions
Interventions
Venglustat (GZ402671)
Locations
6
United States
Inland Empire Liver Foundation Site Number : 8400004
Rialto, California, United States
Clinical Pharmacology of Miami Site Number : 8400002
Miami, Florida, United States
Nucleus Network Site Number : 8400001
Saint Paul, Minnesota, United States
Volunteer Research Group-NOCCR Site Number : 8400003
Knoxville, Tennessee, United States
American Research Corporation Site Number : 8400005
San Antonio, Texas, United States
Investigational Site Number : 2760001
Kiel, Germany
Start Date
January 18, 2023
Primary Completion Date
January 29, 2024
Completion Date
January 29, 2024
Last Updated
September 15, 2025
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions